Cardiac myxoma is a generally benign mesenchymal neoplasm composed of characteristic cells embedded in a myxoid matrix, usually developing on the endocardial surface. Its most common location is the left atrium, where the mass often arises from the interatrial septum near the fossa ovalis. It can, however, involve the right atrium, the ventricles and, more rarely, other cardiac structures. The combination of mobility, variable consistency and an intracavitary location explains why a histologically benign tumor can cause embolism, valvular obstruction or sudden death.
In adults, it is one of the main primary cardiac neoplasms and the most characteristic atrial tumor mass. Most cases are sporadic, while a minority occur in familial forms or Carney complex. The classic presentation includes obstructive, embolic and constitutional manifestations, which can occur alone or together. This heterogeneity makes an apparently neurological, rheumatological or infectious-disease presentation possible before the cardiac cause is recognized.
The true frequency is difficult to estimate because much of the evidence comes from autopsy, echocardiographic or surgical series. In the population-based study by Cresti and colleagues, myxoma accounted for approximately half of the primary tumors identified, with an estimated incidence of 0.68 cases per 100,000 inhabitants per year in the area studied. Sporadic forms occur mainly in adulthood and show a female predominance, whereas syndromic forms can occur earlier and have a less typical distribution. Nevertheless, no age group is excluded.
Recognition has an immediate practical consequence: a mass compatible with myxoma requires prompt cardiac surgical assessment. This need is not driven by malignant transformation, which is not the usual clinical concern, but by the possibility of mechanical and embolic events that cannot be predicted from lesion diameter alone.
No single environmental cause has been demonstrated in sporadic forms. Common atherosclerotic risk factors may be present, but they do not explain tumor development. The most widely accepted histogenetic hypothesis proposes an origin from primitive cardiac mesenchymal cells capable of multiple lines of differentiation. Expression of different markers and the frequent perivascular arrangement support a relationship with endocardial differentiation programs, without conclusively identifying one progenitor cell. The term myxoma therefore denotes a morphologically defined neoplasm, not a mere accumulation of mucous material.
The most important familial form is associated with Carney complex, an autosomal dominant syndrome characterized by variable combinations of myxomas, cutaneous and mucosal pigmentation, and endocrine or other tissue lesions. A substantial proportion of patients harbor inactivating pathogenic variants of PRKAR1A, the gene encoding the type I-alpha regulatory subunit of protein kinase A. Loss of adequate control over the cAMP pathway and protein kinase A alters growth and differentiation signals, promoting neoplastic predisposition. This mechanism is documented in syndromic forms and must not automatically be attributed to every sporadic myxoma.
Onset at a young age, ventricular or atypical locations, multiple concurrent masses, recurrences and a family history increase concern for inherited predisposition. Their presence informs counseling, but none of these findings alone establishes the syndrome. A negative family history does not rule out a de novo variant, and a variant of uncertain significance is not equivalent to a molecular diagnosis. Evaluation should also look for extracardiac manifestations, including characteristic lentiginosis, cutaneous myxomas and signs of endocrine hyperfunction.
The distinction between sporadic and syndromic disease mainly changes surveillance. In the former, complete removal may resolve the local problem; in the latter, a predisposition to new lesions persists, even in other cardiac chambers. Thus, a subsequent mass does not necessarily mean incomplete excision of the original tumor.
Macroscopically, a myxoma is often pedunculated, with a base attached to the septum and a body protruding into the cavity. Its consistency may be gelatinous, friable or relatively firm; hemorrhage, fibrin and calcifications make the appearance heterogeneous. Some lesions have a smooth surface and polypoid shape, while others have a villous or irregular contour. This variability has clinical implications: fragile components exposed to blood flow may fragment, whereas a firm, mobile mass may mainly interfere with passage through a valve. However, the distinction does not define absolute risk categories, since surface thrombosis and embolization can occur with different morphologies.
Microscopy reveals stellate or polygonal cells, isolated, arranged in short cords or distributed around vascular structures, embedded in a myxoid matrix. Hemosiderin deposits, hemorrhage, fibrotic areas, calcifications and inflammatory infiltrates may coexist. Immunohistochemistry helps in uncertain cases: calretinin is a useful marker, while expression of other antigens varies according to the components examined. No single stain replaces morphology, adequate sampling and concordance with the anatomical site.
Identifying a myxoid area is not sufficient to diagnose myxoma. Organized thrombi and malignant tumors with a myxoid matrix may pose differential diagnostic problems; significant atypia, proliferative activity and infiltrative behavior require specialist reassessment. The pathologist must also distinguish any thrombotic or degenerative components from actual neoplastic tissue.
The obstructive effect depends on the relationship between the mass, its stalk and the atrioventricular orifice. A left atrial myxoma can prolapse toward the mitral valve during diastole and impair ventricular filling, producing physiology similar to mitral stenosis. Increased atrial pressure is transmitted to the pulmonary circulation, causing dyspnea and, in more advanced cases, pulmonary edema and right ventricular overload. Cardiac output may fall abruptly if the mass temporarily occludes the orifice. Body position, heart rate and loading conditions can alter the degree of interference and explain symptom variability.
A right atrial myxoma may obstruct the tricuspid valve or venous return, producing systemic congestion, hepatomegaly, edema and low cardiac output. Ventricular lesions may interfere with outflow tracts or valvular apparatuses. Repeated contact injury may promote regurgitation, and a lesion impairing flow need not be infiltrative. The anatomical description must therefore be accompanied by functional measurements: maximum size alone does not convey the hemodynamic burden.
Embolism may involve tumor fragments, adherent thrombotic material or a combination of both. With left-sided lesions, the brain is a clinically important target, but the retina, limbs, kidneys, mesentery and coronary arteries may also be affected. A right-sided lesion can release material into the pulmonary circulation; systemic embolism from a right-sided mass requires right-to-left passage under suitable conditions. Size is not an adequate indicator: a relatively small, friable lesion can embolize before causing significant obstruction. Distinguishing embolic from obstructive risk is essential when setting treatment priorities.
Systemic manifestations are partly related to production of interleukin-6 and other mediators. Experimental studies by Jourdan and colleagues documented interleukin-6 production by myxomas, providing a biological explanation for the inflammatory response and certain immunological abnormalities. Acute-phase stimulation and immune activation contribute to fever, fatigue, anemia and elevated inflammatory markers. This mechanism can precede hemodynamic signs and prompt a prolonged search for systemic diseases.
However, this association does not make cytokine measurement a stand-alone diagnostic test. Interleukin-6 is involved in numerous conditions, and its concentration neither specifically identifies a myxoma nor, by itself, establishes the need for or timing of surgery.
History-taking begins by establishing the duration and variability of symptoms. Exertional dyspnea, orthopnea, reduced exercise tolerance, presyncope and syncope may suggest intermittent obstruction to filling. Worsening in certain positions or symptoms seemingly disproportionate to previous cardiac diagnoses deserve attention but are not specific to myxoma. Pulmonary edema or hypotension may indicate an emergency, whereas a slowly progressive course may mimic common valve disease.
Palpitations or an irregular pulse warrant a search for concomitant arrhythmia. Atrial fibrillation may result from atrial remodeling or other heart disease and introduces another potential source of embolism. Its presence does not prove that the mass is a thrombus, just as identifying a myxoma does not remove the need to assess arrhythmia-related risk separately.
Neurological and vascular history should seek episodes of focal deficits, sudden visual disturbances, peripheral ischemia and acute pain consistent with involvement of other vascular territories. Events in different territories or recurrences without a convincing explanation increase suspicion of a central source. Documented events should be distinguished from the patient's recollection by reviewing available reports and images. A myxoma provides a plausible cause, but definitive attribution requires comparison with atherosclerosis, atrial fibrillation and other embolic sources.
Fever, sweating, weight loss, arthralgia and fatigue may dominate the presentation. An inflammatory syndrome without an identified focus, particularly with cardiac or embolic symptoms, should raise this possibility. The complete triad is often absent: investigations should not be delayed until obstruction, embolism and constitutional symptoms are all present.
The medical history includes previous cardiac neoplasms, operations, echocardiograms, antithrombotic treatment and family history. In younger patients or those with recurrence, features suggestive of Carney complex are sought. Prior resection does not justify automatically considering every new finding benign; instead, the site, morphology and original histological diagnosis must be compared. A previous negative echocardiogram must also be interpreted in light of its quality, how long ago it was performed and examination completeness.
Physical examination initially assesses perfusion, blood pressure, heart rate and congestion. A left-sided myxoma may cause a diastolic murmur or findings varying throughout the cardiac cycle; occasionally an early diastolic sound, traditionally termed the tumor plop, is heard as the mass moves and stops. In the historical series by Pinede and colleagues comprising 112 left atrial myxomas, this finding occurred in only a minority. Its absence therefore has little exclusionary value, and its presence does not replace echocardiography.
Crackles, signs of pulmonary hypertension, jugular distension or edema depend on the severity and site of obstruction. Neurological and pulse examinations may reveal embolic injury. Skin and mucous membranes are examined for syndromic signs when indicated. Few noteworthy findings are still possible, especially with incidentally detected lesions or after an embolic event without major flow impairment.
Transthoracic echocardiography is generally the initial investigation. A mobile, pedunculated atrial mass attached to the left side of the septum near the fossa ovalis is highly suggestive. The examination should determine dimensions in multiple planes, surface characteristics, heterogeneity, mobility and attachment site, and assess valvular prolapse and Doppler consequences. Other chambers must also be examined, especially in familial or recurrent forms. A typical location increases diagnostic probability but is not, by itself, histological confirmation.
Hemodynamic assessment documents the gradient across the involved orifice, regurgitation, atrial dimensions, ventricular function and estimated pulmonary pressures. These data must be interpreted alongside heart rate and flow: a gradient varies with loading conditions and is not an immutable property of the mass. Intermittent obstruction may require particular attention to dynamic sequences. In unstable patients, bedside echocardiography can rapidly identify the mechanism and guide urgent management.
Transesophageal echocardiography is indicated when clarification is needed regarding the stalk, an atypical site, a small lesion or relationships not adequately seen transthoracically. Three-dimensional acquisitions can make the attachment base and its relationship to the valve easier to understand, facilitating operative planning. Additional masses and concurrent embolic sources should be sought. The technique is selected according to expected benefit and patient condition; it must not delay urgent treatment if the essential information is already available.
Cardiac magnetic resonance imaging is particularly useful for atypical masses or unresolved differential diagnoses. Myxoma often has heterogeneous signal characteristics influenced by water, matrix, hemorrhage, fibrosis and calcifications. Cine sequences show movement and attachment; perfusion and postcontrast enhancement may be variable and heterogeneous. Viable tissue may enhance, whereas thrombotic or degenerative areas may behave differently. No combination of signals is invariably present in every myxoma.
Lack of perfusion or enhancement favors thrombus in some contexts, but organized thrombi can show complex behavior and a tumor may contain avascular areas. The conclusion rests on concordance between anatomy, tissue features and the clinical situation, rather than treating one sequence as a definitive test.
Cardiac CT can depict the lesion, calcifications and relationships with nearby structures, and is an alternative if MRI cannot be performed. Cardiac gating and an appropriate contrast protocol improve definition; a non-dedicated chest examination may detect the mass without correctly characterizing its stalk. In suitable patients, CT may also contribute to preoperative coronary assessment. PET is not a routine step for a typical myxoma: metabolic activity is not itself evidence of malignancy and must be interpreted in context.
The main alternative is an intracardiac thrombus. Atrial fibrillation, atrial dilation, mitral stenosis, blood stasis and an appendage location support this possibility; a pedunculated septal attachment instead favors myxoma. However, organized thrombi may resemble tumors, while myxomas may occur at unconventional sites. A trial of anticoagulation may be reasonable only in selected situations with a substantial likelihood of thrombosis and a risk compatible with waiting. It must not routinely delay treatment of a highly mobile, emboligenic or obstructive mass considered neoplastic.
Infective vegetations are considered particularly in the presence of bacteremia, valvular damage and a compatible clinical presentation. Fever alone does not distinguish endocarditis from myxoma because the tumor itself can produce an inflammatory syndrome. Sterile vegetations warrant investigation of a neoplastic or autoimmune context when appropriate. Fibroelastoma, usually small and valvular, differs in morphology and attachment, whereas lipomas and fatty pseudomasses can be identified by their tissue composition.
Important diagnoses not to miss include atrial sarcomas, some of which can mimic a myxoma. A broad base, infiltration, extension through pulmonary veins, rapid growth or extracardiac involvement warrant particular caution. These findings must also be considered together, since a benign mass may be large and heterogeneous while an early malignant lesion may lack some expected features. Radiological suspicion guides the work-up, but definitive distinction in uncertain cases requires pathological examination.
A complete blood count, C-reactive protein and other tests may document anemia and inflammation but do not confirm the diagnosis. Blood cultures are appropriate when infection is suspected and should be interpreted before attributing fever to the tumor. The electrocardiogram may show arrhythmias or signs of overload without providing a specific finding. There are no universal clinical criteria or validated score that can replace imaging and histology in myxoma.
Confirmation usually comes from the surgical specimen. A preliminary intracardiac biopsy is generally unnecessary for a typical resectable mass and can add a risk of fragmentation or embolism. If the behavior suggests another diagnosis, the sampling strategy is discussed by an expert team according to its actual potential to change treatment.
The next priority is to determine urgency. Instability, pulmonary edema, critical obstruction or recent embolic events warrant rapid assessment in an appropriate setting. Resection is nevertheless arranged promptly in stable patients, avoiding delays without a clinical reason. There is no single time limit expressed in hours or days that is applicable to everyone: priority depends on mobility, the mechanism of symptoms, general condition and associated risks.
Neurological investigations are guided by the history and clinical examination. Following a cerebral event, CT or MRI defines its location, extent and any hemorrhagic component; vascular imaging is added when necessary. These findings influence surgical timing because cardiopulmonary bypass requires anticoagulation and may increase the risk of hemorrhagic transformation of a recent lesion. Neurologists, cardiac surgeons, cardiologists and anesthesiologists jointly weigh the danger of another embolus or obstruction against perioperative neurological risk. A rigid waiting period imposed without considering the severity of both risks is inappropriate.
Preoperative evaluation includes renal function, hematological status, comorbidities and respiratory condition, as well as a precise description of the septum, valves and chambers involved. Investigation for coronary artery disease is individualized according to age, symptoms, clinical probability and type of surgery. Invasive testing is not required in every young patient without specific indications; coronary CT may address the question in selected cases. When attachment or extension is uncertain, targeted anatomical assessment is more useful than indiscriminate multiplication of imaging techniques.
Genetic and endocrine assessment is indicated when the phenotype suggests Carney complex. It coordinates test interpretation, the search for associated manifestations and any assessment of family members. Family surveillance strategies depend on the clinical and molecular diagnosis, not simply on the presence of a myxoma at an older age. Typical sporadic cases do not require systemic oncological staging or a generalized tumor-screening program. Additional investigations must be justified by specific findings, not merely by use of the term neoplasm.
Complete resection is the treatment of choice. The goal is to remove the mass and its attachment while preventing dispersal of fragments and preserving cardiac function. The procedure is usually performed with cardiopulmonary bypass; the surgical approach is selected according to site, dimensions, anatomical relationships, need for associated procedures and center expertise. Minimally invasive or robotic approaches are possible in selected patients, but reducing the size of the access must not compromise visualization, complete excision or specimen integrity.
Manipulation of the mass is minimized to limit embolization. The stalk and attachment base must be identified precisely; excision of part of the septum and reconstruction by suture or patch are tailored to the extent. There is no universally mandatory margin in millimeters for every myxoma: the goal is adequate removal of the attachment while respecting adjacent structures. Searching for additional lesions and checking the chambers becomes particularly important in multiple or syndromic forms.
Intraoperative echocardiography verifies valve function and the absence of significant residual lesions, unwanted septal communications or new hemodynamic abnormalities. The excised tumor is always sent for pathological examination, even if imaging was highly characteristic.
Associated regurgitation may improve once mechanical interference is removed, but structural injury to the leaflets or subvalvular apparatus may require repair. Valve replacement is not an obligatory component of myxoma surgery; the decision depends on the actual lesion. Likewise, any treatment for coronary artery disease or other cardiac conditions follows its own indications, assessed in the overall clinical context. Careful preparation helps distinguish reversible consequences of the mass from conditions requiring an additional procedure.
Medical therapy mainly serves to stabilize the patient. Congestion and arrhythmias are managed with consideration of possible filling obstruction; excessive reduction in preload may be poorly tolerated when obstruction is significant. Anticoagulants or antiplatelet agents may have independent indications or be considered for thrombotic components, but they neither eliminate neoplastic tissue nor guarantee protection against embolization of fragments. The absence of new events during antithrombotic treatment does not prove that the mass has become safe.
In patients with acute stroke, initial management requires urgent neurological assessment, identifying occlusion and any hemorrhagic component. The potentially tumoral nature of the embolus and the paucity of specific evidence call for specialist decisions about reperfusion therapies; a strategy should not be inferred solely from the cardiac diagnosis. The timing of subsequent resection is chosen by balancing neurological risk against ongoing embolic risk. Intracranial hemorrhage, a large ischemic area and a mass causing critical obstruction pose different problems.
If operative risk is prohibitive or surgery is not feasible, management must explicitly acknowledge the residual risk. No drug treatment has demonstrated efficacy in causing an ordinary myxoma to regress. Options include treating complications, possible antithrombotic treatment for justified indications and follow-up compatible with the goals of care. Experimental or exceptional alternative approaches do not replace established surgery in the general population. Decisions require multidisciplinary discussion, particularly when frailty or comorbidities substantially alter the expected benefit.
Prognosis after excision is generally favorable, particularly in sporadic cases treated before irreversible damage occurs. Removing the obstruction may rapidly improve hemodynamic symptoms, while the inflammatory response tends to subside once its source is eliminated. Actual recovery nevertheless depends on existing consequences, cardiac function and concomitant diseases. Anatomical cure does not reverse an established neurological deficit and does not automatically alter vascular risk arising from other causes.
In the series by Jiang and colleagues comprising 403 patients operated on for atrial myxoma, early mortality was 0.7%; six recurrences were observed over a median follow-up of 4.5 years. Late atrial fibrillation was also a clinically significant outcome. These results support good surgical efficacy but describe an observational cohort and do not offer an individual prediction applicable to every center, age group or level of anatomical complexity.
The risk of recurrence is higher in familial, multiple or syndromic cases. Potential mechanisms include local residual disease, initially unrecognized lesions and development of new tumors in a genetically predisposed heart. Appearance in another chamber many years later makes the last possibility particularly relevant. However, not every new mass is a myxoma: thrombi and other lesions require renewed characterization.
Postoperative assessment establishes an echocardiographic baseline and checks valve function, the septum and cardiac chambers. Surveillance frequency and duration are then individualized according to completeness of resection, syndromic status, age and history of recurrence. Periodic echocardiography is customary, while patients with Carney complex require closer and more prolonged surveillance coordinated with extracardiac follow-up. There is no single universally validated schedule for all sporadic myxomas.
New dyspnea, syncope, embolic symptoms, recurrence of an inflammatory syndrome or palpitations warrant reassessment ahead of schedule. Follow-up also includes detecting arrhythmias and managing conventional cardiovascular risk factors, since subsequent events do not arise exclusively from tumor recurrence.
The most feared acute complications are critical obstruction and embolism. Mitral involvement can cause pulmonary edema and shock; tricuspid involvement can lead to severely reduced output and congestion. Cerebral embolization can cause stroke with permanent disability, while coronary embolization can produce acute myocardial ischemia. Peripheral, renal or mesenteric involvement requires urgent vascular assessment specific to the territory involved. Sudden death may result from any of these mechanisms even without a long preceding history of symptoms.
A rare complication is the development of cerebral aneurysms associated with embolization of myxoma cells into the vascular wall. These can be multiple and may become apparent even after cardiac resection, without intracardiac recurrence. This behavior does not automatically mean that a sarcoma is present: the mechanism involves lodging and local effects of embolized tumor material. The natural history varies and evidence comes mainly from case reports and small series, so surveillance and possible neurovascular treatment must be individualized.
Thus, new neurological symptoms in an operated patient should not be dismissed as impossible consequences of myxoma, but neither should they automatically be attributed to it. Brain and vascular imaging is guided by the clinical presentation and previous history; no universal invasive surveillance program has been demonstrated for every asymptomatic patient after resection.
Infection of a myxoma is rare and may involve bacteremia, septic emboli and greater treatment complexity. Suspicion warrants blood cultures and infectious-disease assessment, distinguishing infection from cytokine-mediated fever. Treatment combines antimicrobial therapy and surgical management according to clinical circumstances. Hemorrhage within the mass or extensive surface thrombosis can also change its morphology and behavior, explaining changes in presentation without true biological transformation.
Postoperative complications include bleeding, neurological events, arrhythmias, conduction disorders, valvular dysfunction and problems related to septal reconstruction, with risks varying according to the procedure. Atrial fibrillation may develop early or during follow-up and requires independent evaluation of antithrombotic indications. An unexpected histological diagnosis ultimately calls for a reassessment of prognosis and treatment. Integrating surgical findings, pathology and follow-up imaging makes it possible to distinguish curative resection from a situation requiring further procedures or investigations.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.